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LIST OF ABBREVIATIONS 
BO; Barrett’s oesophagus 
BMI; body mass index 
CI; confidence interval 
CRF; case record form 
OAC; oesophageal adenocarcinoma 
HGD; high-grade dysplasia 
IHC; immunohistochemistry 
IMC; intramucosal carcinoma 
IND; indefinite for dysplasia 
IQR; interquartile range 
K; kappa value 
LGD; low-grade dysplasia 
NDBO; non-dysplastic Barrett’s oesophagus 
OR; odd’s ratio 
WSI; whole slide imaging 
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ABSTRACT 
Objective: Guidelines mandate expert pathology review of Barrett’s oesophagus (BO) 
biopsies that reveal dysplasia, but there are no evidence-based standards to corroborate 
expert reviewer status. We investigated BO concordance rates and pathologist features 
predictive of diagnostic discordance. 
Design: Pathologists (n=51) from over 20 countries assessed 55 digitised BO biopsies from 
across the diagnostic spectrum, before and after viewing matched p53 labelling. Extensive 
demographic and clinical experience data were obtained via online questionnaire. Reference 
diagnoses were obtained from a review panel (n=4) of experienced Barrett’s pathologists.  
Results: We recorded over 6,000 case diagnoses with matched demographic data. Of 2,805 
H&E diagnoses, we found excellent concordance (>70%) for non-dysplastic BO and high-
grade dysplasia, and intermediate concordance for low-grade dysplasia (42%) and indefinite 
for dysplasia (23%). Major diagnostic errors were found in 248 diagnoses (8.8%), which 
reduced to 232 (8.3%) after viewing p53 labelled slides. Demographic variables correlating 
with diagnostic proficiency were analysed in multivariate analysis, which revealed that at least 
5 years of professional experience was protective against major diagnostic error for H&E slide 
review (OR 0.48, 95%CI 0.31-0.74). Working in a non-teaching hospital was associated with 
increased odds of major diagnostic error (OR 1.76, 95%CI 1.15-2.69), however this was 
neutralised when pathologists viewed p53 labelled slides. Notably, neither case volume nor 
self-identifying as an expert predicted diagnostic proficiency. Extrapolating our data to real-
world case prevalence suggests that 92.3% of major diagnostic error is due to overinterpreting 
non-dysplastic Barrett’s oesophagus.  
Conclusion: Our data provide evidence-based criteria for diagnostic proficiency in Barrett’s 
histopathology. 
 
 
What is already known about this subject? 
Pathology evaluation of Barrett’s patients’ surveillance biopsies is poorly reproducible. 
Guidelines mandate that biopsies with dysplasia be reviewed by an expert, but there are 
no evidence-based criteria to corroborate expert reviewer status.  
 
What are the new findings? 
Through a large online consensus study amongst more than 50 pathologists in over 20 
countries we reveal histopathologist-dependent predictors of major diagnostic error in the 
assessment of Barrett’s biopsies. The size of our dataset allows us to quantify the impact of 
these variables, such as experience commensurate with age and professional setting, in 
multivariate analysis.   
 
How might it impact on clinical practice in the foreseeable future? 
Our data provide evidence-based criteria for diagnostic proficiency in Barrett’s histopathology 
and will help facilitate training and support to reduce diagnostic variability.  
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INTRODUCTION 
Barrett’s oesophagus (BO) is a premalignant condition, which predisposes to oesophageal 
adenocarcinoma (OAC), with a reported annual conversion rate of 0.1 - 0.2%. 1-3 BO is defined 
histopathologically as the replacement of normal stratified squamous epithelial lining of the 
distal oesophagus with columnar epithelium that can contain intestinal metaplasia. The 
implementation of formal surveillance strategies and widespread adoption of endoscopic 
treatment techniques, such as endoscopic resection and ablation for dysplastic BO, have led 
to a surge in diagnostic pathology workload. The goal of endoscopic surveillance and biopsy 
verification is objective risk stratification for patients according to their perceived progression 
risk to OAC.  
Previous studies have revealed, however, that diagnostic reproducibility (inter-observer 
agreement) amongst pathologists grading dysplastic BO biopsy material is moderate to poor, 
even amongst expert reviewers (Supplementary Table 1). 4-17 Previous work from our group 
has shown that central pathology review by a dedicated panel within the context of prospective 
intervention trials failed to confirm an initial diagnosis of low-grade dysplasia (LGD) in over 
three-quarters of cases submitted for panel review. On follow up, cases that had been 
downgraded to non-dysplastic BO (NDBO) revealed a nominal progression risk of about 0.5% 
per patient/year, whilst cases that had been confirmed LGD on central review showed a 
progression risk of about 10% per patient/year. These data clearly attest to the clinical return 
of dedicated pathology review. 18 19 International BO management guidelines now mandate 
histopathology review of all BO biopsy cases found to reveal dysplasia by an independent 
expert pathologist. 20 21 However, whilst major society guidelines have qualitatively defined an 
expert BO pathologist as ‘a pathologist with a special interest in BO-related neoplasia who is 
recognised as an expert in this field by their peers’, we lack firm evidence-based standards to 
corroborate expert reviewer status. 21-26 This now represents an acute unmet need as these 
considerations also carry important medico-legal implications.  
 Recently, the US Food and Drug Administration has approved the use of whole slide 
imaging (WSI) for primary diagnostic use. 27 The advantages of WSI are numerous and include 
simultaneous assessment by multiple pathologists, streamlined expert consultation, and digital 
image analysis. It is expected that digital pathology will rapidly gain widespread acceptance in 
the coming years, in particular in the context of distant case review. A number of large-scale 
diagnostic consensus studies have been performed, which have broadly suggested that the 
diagnostic discordance rate between pathologists using digital slide review is non-inferior to 
conventional glass slide diagnosis. 28-30 However, these studies generally examined a large 
number of diagnostic categories without focusing on a particular category of known diagnostic 
discordance such as Barrett’s dysplasia. Establishing the validity of this new technology to BO 
histopathologic workup is therefore a clear priority. 
 Here we set out to develop quantitative standards of expert reviewer status for guideline 
development purposes using massive online digital pathology reporting. We define expert 
reviewer status as evidence of diagnostic concordance on a par with consensus within an 
expert review panel, acknowledging that, in lieu of an objective biomarker of progression risk, 
there will be diagnostic variation amongst expert pathologists. We collected extensive 
demographic information of participating pathologists to understand operator-dependent 
predictors of diagnostic variation. 
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METHODS 
Ethical considerations 
This study utilised anonymised archived formalin-fixed, paraffin embedded material and did 
not require approval from the relevant Institutional Ethics Committee under applicable local 
regulatory law (‘Code of conduct’, FEDERA). 
 
Assessors 
Sixty-five gastrointestinal pathologists worldwide were approached to join this study through 
either professional gastrointestinal pathology working groups or direct professional contacts. 
Fifty-nine pathologists responded positively to our enquiries and were recruited to this study of 
which 51 pathologists completed the entire case set of 55 H&E-stained and 55 matching p53 
immunohistochemistry (IHC) labelled slides (110 slides total). These 51 pathologists are 
henceforth referred to as participating pathologists. Participating pathologists received emails 
detailing the study objectives and were provided with personal log-in credentials to the 
purpose-built online scoring environment described below. Lead study author (MvdW) 
provided assistance with participating pathologists’ log-in queries, evaluated study progress, 
and chaired the panel consensus meeting.  
Four BO pathologists (including two study authors, MJ and SM) with extensive 
experience in BO dysplasia assessment reviewed all slides as a reference pathologist panel. 
This group has successfully collaborated on previous BO intervention studies where patient 
outcome has been evaluated prospectively 18 19 31-37 as well as on the Amsterdam Barrett’s 
Advisory Committee. 31 These four pathologists are henceforth referred to as reference 
pathologists.  
 
Slide selection and scanning 
The lead study author selected a representative case-mix of 55 BO biopsy cases from across 
the diagnostic spectrum (Supplementary Table 2). Inclusion criteria were: diagnosis 
confirmed by a second gastrointestinal pathologist; documented clinical follow-up of at least 
one year available; and tissue block available. All cases were treatment-naïve. Per case, 
immunohistochemical staining for p53 was performed using a Ventana Benchmark XT 
autostainer (Ventana Medical Systems, Tucson, AZ).  Antigen retrieval was performed with 
CC1 mild. P53 was detected with p53 Antibody (Mouse DO-7 + BP 53-12, Thermo Scientific) 
and the sections were incubated in a 1:500 dilution for 32 min at room temperature. Bound 
antibody was detected using the Biotin free Ultraview Universal DAB Detection Kit (Roche 
Diagnostics) and slides were counterstained with Hematoxylin (Roche Diagnostics). 38 One 
H&E slide and one consecutive section p53 labelled slide were digitised from each case using 
a scanner with a 20x microscope objective (Slide, Olympus, Tokyo, Japan). Scans were 
checked for focus and acuity by the study coordinator and re-scanned if necessary. 
Subsequently, slides were anonymised, randomised, renamed, and stored on a secure server. 
The ‘Digital Slidebox 4.5’ (https://dsb.amc.nl/dsb/login.php, Slidepath, Leica Microsystems, 
Dublin, Ireland) virtual slide viewing software was used to evaluate the digital slides during the 
study. EMR specimens were not included in our study cohort.  
Electronic scoring environment 
Template electronic Case Record Forms (CRFs) were custom built within a web-based 
software tool designed to capture clinical study data (OpenClinica v3.6, an open source CTMM 
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TraiT project, LLC, Waltham, USA). One CRF consists of an extensive questionnaire 
documenting pathologist characteristics such as age, sex, host institution, and experience in 
reporting BO biopsies and digital pathology (full questionnaire details in Supplementary Table 
3). The second CRF was built to record individual case diagnoses. Importantly, this second 
CRF consists of separate parts to record H&E and H&E plus p53 labelled slide diagnoses 
independently. The first part of the case diagnosis CRF contains a dynamic URL link to the 
scanned H&E slide and includes questions about the slide quality and diagnosis, and whether 
the assessor would require a p53 labelled slide. Importantly, the second part of the templated 
CRF that contains a dynamic link to the p53 labelled slide alongside the matching H&E slide, 
only opens after the study pathologist has completed assessment of the H&E-stained slide and 
saved their case diagnosis for this slide. This second part of the templated CRF, in addition to 
a dynamic link to the matching p53 labelled slide, again included corresponding slide 
assessment questions.  
 
Digital case assessments 
Reference and participating pathologists were asked to assess each case, according to the 
modified Vienna classification for gastrointestinal neoplasia. 39 40 Reference pathologists first 
assessed all cases individually and completed the questionnaire. An online consensus meeting 
was then convened after a two-month wash out period to discuss discrepancies and produce 
reference diagnoses for each of the 110 assessments (55 H&E-stained slides and 55 matching 
p53 labelled slides). The panel assessment was taken forward as the reference diagnosis 
without further discussion if reference panel members achieved a majority diagnosis (i.e. 
concordance between either 3 out of 4 or 4 out of 4 pathologists) on a case directly from their 
independent scoring. Group discussions were held between these four pathologists to review 
and discuss cases for which there was no majority diagnosis to mimic real-world practice. The 
discrepancies where a majority diagnosis had not been reached after individual slide review 
encompassed 21 cases based on H&E slide viewing, and 13 cases based on the p53 labelled 
slide. These cases were reviewed during the panel discussion (21 H&E slides reviewed without 
matching p53 labelled slide, and 13 cases with H&E-stained slide and matching p53 labelled 
slides) to arrive at a consensus diagnosis for all 110 assessments.  
From the case assessments by the participating pathologists, two post-p53 labelled 
case assessments were inadvertently left blank by individual participating pathologists (one 
each) after evaluating the case H&E slide. Results from the matching H&E slides were imputed 
as post-p53 case diagnosis in these cases, based on the H&E slide score, corresponding to 2 
HGD diagnoses.   
Population estimates 
To extrapolate our findings to the proportional prevalence of Barrett’s dysplasia in real-world 
practice, we used incident and surveillance reports from the population-based Northern Ireland 
Barrett’s oesophagus register, methods of which have been described elsewhere. 41 42 The 
prevalence for the most recently available data in 2014 were applied, in which n=2,872 patients 
received a pathology diagnosis of NDBE (n=2,627, 91.5%), IND (n=36, 1.2%), LGD (n=85, 
3%) or HGD (n=124, 4.3%).  These values were then used to estimate the population impact 
of interpretation discordance for each diagnostic category.    
 
Statistical analysis  
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Characteristics of the four reference pathologists and the 51 participating pathologists were 
compared informally. We examined the overall concordance of the study pathologists 
compared to the consensus reference diagnosis per case. This process was conducted for 
each of the four individual members of the reference panel against the final consensus 
diagnosis of this panel, as well as for the overall sample of 51 pathologists against the 
consensus diagnosis. Per pathologist scores were not calculated, since we aimed to study the 
cohort behavior rather than the individual pathologist. Concordance was initially compared 
based on four relevant diagnostic categories (NDBO, IND, LGD, HGD), and then compared 
based on three relevant diagnostic categories (NDBO, IND, LGD or HGD) to reflect the fact 
that HGD and LGD are now treated endoscopically in some settings. 32 We calculated 95% 
CIs for overall concordance and per diagnostic category. Since this cohort was strongly 
enriched for dysplasia, we did not use kappa statistics, since these are less reliable when cross 
tables are skewed. 
To evaluate the potential clinical impact of discordant interpretations across the cohort 
of participating pathologists, we then reclassified all discordant assessments as either major 
or minor discordances. Major overinterpretation is defined as NDBO reference diagnosis 
overinterpreted as either LGD or HGD, whereas, vice versa, major underinterpretation is LGD 
or HGD reference diagnosis underinterpreted as NDBO by the participating pathologist. These 
discordant interpretations would bear major consequences in clinical practice. All other 
discordant interpretations were classified as minor discordant interpretations. A tabular 
overview of interpretation classifications as major or minor is shown in Supplementary Table 
4. Since both major overinterpretation and major underinterpretation can have negative 
implications for patient management, these were further combined for the purposes of some 
analyses, as indicated.  
Unadjusted logistic regression analyses were then conducted to identify any 
pathologist characteristics that were associated with overall and major over or 
underinterpretation of BO cases compared to the consensus diagnosis. Considering that age 
and professional experience are inextricably linked, we evaluated individual combinations of 
age and experience for odds of major over and underinterpretations, and combined these into 
three categories in whom similar odds ratios were observed (Supplementary Table 5). 
Forward selection of significant factors was used to create multivariable-adjusted logistic 
regression models of characteristics associated with misinterpretation. Although routine use of 
p53 immunohistochemistry was not associated with diagnostic errors, this was retained in 
multivariate models for p53 stained slides. All statistical analyses were performed using Stata 
version 14.2 (StataCorp., College Station, TX, USA).  
 
RESULTS 
Study design 
This study is based on assessments of digitised slides to investigate diagnostic concordance 
of BO biopsies amongst a large and heterogeneous sample of gastrointestinal pathologists. 
We investigated rates and features predictive of diagnostic concordance amongst these 
pathologists, with a particular focus on the demographic characteristics of the pathologists, the 
impact of viewing p53 labelled slides alongside H&E-stained slides, and on features associated 
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with major diagnostic discordance that would negatively impact upon patient stratification and 
treatment pathways. The purpose of this study was to build a quantitative model of expert BO 
pathologist review characteristics, and to provide practical recommendations that could 
minimize errors in the interpretation of BO biopsies in the routine setting.   
The study flowchart is shown in Figure 1A. All pathologists first filled out a baseline 
questionnaire for detailed demographic and clinical experience data. Pathologists then 
assessed the 110 digitised slides (55 H&E slides and matching p53 labelled slides) and 
recorded their answers on dedicated electronic CRFs. As detailed in the methods section, 
diagnostic entries were recorded after viewing the H&E-stained slide and again after the 
matched p53 labelled slide was revealed alongside the case H&E slide.  
The entire study set was completed by fifty-five pathologists working in over 20 
countries and 5 continents (Figure 1B). Of these fifty-five pathologists, 4 pathologists with 
extensive and published experience in BO dysplasia assessment were designated beforehand 
as reference pathologists. 18 19 32 43 44 In sum, with 55 pathologists reviewing 55 biopsy cases, 
each of which includes one H&E-stained slide and a matched p53 labelled slide, this generated 
a massive dataset of over 6,000 case diagnoses with matched demographic data as input data 
for our Barrett’s digital pathology (BOLERO) consensus study, one of the largest digital 
pathology consensus studies reported thus far. Case diagnoses were compared to reference 
diagnoses and we searched for pathologist demographic features that predict diagnostic 
consensus at expert level.  
Patient characteristics of BO biopsy samples  
Patient characteristics of the sample biopsies are shown in Supplementary Table 2. Of these 
patients, 94.5% was male (52/55). The median age at diagnosis was 65, the median BMI was 
27, the median BO segment length was Circumferential (C) 4 cm, Maximum (M) 5 cm. Patients 
had a history of smoking in 63.6% of cases (35/55), a history of heartburn symptoms in 89% 
of cases (49/55), and used anti-reflux medication in 96.4% of cases (53/55).  
 
Pathologist characteristics 
Baseline characteristics of the pathologists taking part in the study are displayed in Table 1 
and Supplementary table 6. Participating pathologists represented a heterogeneous sample 
comprising a wide range of ages, workplace settings (academic teaching, private and/or district 
general hospital settings) and years of professional experience. Just over 50% of participating 
pathologists reported dedicated fellowship experience, whilst the majority (72%) worked in a 
large laboratory with ≥10 pathologist colleagues. The most commonly reported guidelines to 
which pathologists adhered were North American, British, or Japanese, however a quarter of 
pathologists reported using other guidelines in their clinical practice. Two thirds of participating 
pathologists self-identified as expert gastrointestinal pathologists. Note that although 
pathologists were approached through professional societies, no effort was made to purposely 
recruit experts onto the study. Pathologists also reported on other parameters and working 
practices in their laboratories, such as typical numbers of BO cases reported per week, 
confidence and enjoyment in reporting BO, reporting of endoscopic resection specimens, 
frequency of adjunct p53 labelled slide use in BO reporting, participation in double-reporting, 
multi-disciplinary team meetings, and use of WSI, as well as typical interactions and 
perceptions of practices of their endoscopy colleagues (Table 1 and Supplementary table 6). 
Participating and reference pathologists were generally well matched for age ranges and 
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professional experience although all four reference pathologists were male, whereas 22 of 51 
(43.1%) participating pathologists in the larger cohort were female. 
 
Case assessment overview 
A total of 3,025 diagnoses were generated based on H&E-stained slide case review and 
another 3,025 diagnoses were recorded after viewing the matching p53 labelled slides for 
study cases (Figure 2A and B). The corresponding waterfall plots showing the ranked 
distribution of assessments reveal a gradual transition from NDBO examples with high 
interobserver concordance to HGD cases with similarly high interobserver concordance and 
diagnostic categories where concordance gradually transitions between these extremes. 
These plots also confirm that our case set includes representative biopsies from across the 
diagnostic spectrum of BO pathology. Relevant examples of study cases are shown in Figure 
2C.  
Concordance of reference pathologists vs. consensus diagnosis on H&E and p53 
labelled slides 
Consensus diagnoses were generated following panel review. The reference panel consensus 
diagnoses for the H&E-stained slide case review included 16 NDBO, 6 IND, 18 LGD, and 15 
HGD case diagnoses. After the addition of matched p53 labelled slides and reference panel 
review a small number of cases were reclassified, including 1 NDBO diagnosis as LGD, 1 LGD 
diagnosis as NDBO, and 4 IND diagnoses as LGD, thus totaling 16 NDBO, 2 IND, 22 LGD and 
15 HGD after p53 labelled slide review.   
Individual consensus panel member diagnoses were then compared to the final 
consensus panel diagnosis to obtain concordance rates between the 4 reference pathologists. 
This revealed excellent diagnostic agreement when reporting NDBO, LGD and HGD on H&E-
stained slides alone (84.4%, 65.3% and 78.3%, respectively), rising to 89.4% when LGD and 
HGD diagnoses were combined. After revealing the matching p53 labelled slide for the 55 
cases, agreement further improved to 85.9% for ND, 72.7% for LGD, and 76.7% for HGD, 
rising to 91.9% when LGD and HGD were combined (Supplementary Tables 7A and B).  
Concordance of participating pathologists vs. consensus diagnosis on H&E and p53 
stained slides 
The complete set of 5,610 case assessments recorded by the 51 participating pathologists 
was then compared to the reference panel diagnoses to obtain concordance rates and 
compare diagnostic agreement within and between categories. The diagnostic agreement 
between 51 participating pathologists for H&E-stained slide diagnoses is depicted in Figure 
3A-C and Supplementary Figure 1A, while concordance percentages are shown in Table 
2A. We found excellent concordance between the participating pathologists for NDBO 
reference diagnosis cases (643 of 816 diagnoses; 78.8%) and HGD reference diagnosis cases 
(544 of 765 diagnoses; 71.1%). As expected, there was moderate concordance for LGD 
reference diagnosis cases (382 of 918; 41.6%) and poor concordance for IND reference 
diagnosis cases (70 of 306; 22.9%). However, if dysplastic assessments were grouped (i.e. 
combining LGD and HGD reference diagnosis cases) then 77.5% (1,305 of 1,683) of cases 
were concordant. Major over or underinterpretation was found in 8.8% of assessments (248 of 
2,805 diagnoses).  
Addition of matched p53 labelled slides improved diagnostic concordance (Figure 3D-
F and Supplementary Figure 1B) with small but clinically meaningful improvements seen in 
the diagnostic concordance between participating pathologists for NDBO reference diagnosis 
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cases (83.8% v. 78.8% on H&E slide) and LGD/HGD combined reference diagnosis cases 
(79.3% v. 77.5% on H&E slide), Table 2B. In addition to this, p53 labelled slides also had a 
small but beneficial impact on reducing the number of major over and underinterpretations 
(8.3%, 232 of 2,805 diagnoses), representing 0.5% fewer overall major misinterpretations 
compared to H&E-stained slide diagnosis alone.  
Characteristics associated with concordance on H&E slides 
This massive dataset was then interrogated to reveal histopathologist predictors of over or 
underreporting and major diagnostic errors in univariate analysis. To this end all diagnostic 
discordances within our dataset (i.e. case diagnoses not matching reference diagnosis) were 
first reclassified as major or minor over or underinterpretation (see Methods and 
Supplementary Table 4). Factors associated with reduced odds of major diagnostic errors 
included: ≥5 years of experience commensurate with age (OR 0.65, 95%CI 0.45-0.93); working 
in an academic teaching hospital (OR 0.59, 95%CI 0.43-0.81); routinely double reporting 
indefinite for dysplasia cases (OR 0.70, 95%CI 0.52-0.94); working in a larger lab (≥10 versus 
<10 pathologists OR 0.72, 95%CI 0.54-0.96) and using digital pathology (OR 0.63; 95%CI 
0.47-0.89). In contrast, working within a district general hospital (OR 1.72, 95%CI 1.30-2.26) 
or private hospital (OR 1.41, 95%CI 1.04-1.91), or not using major society guidelines (OR 1.43, 
95%CI 1.06-1.94) were all associated with increased odds of major diagnostic errors 
(Supplementary Tables 8A-C).  
Several factors were not associated with major diagnostic error, including pathologist 
sex. Participating in upper gastrointestinal multidisciplinary team meetings was not associated 
with reduced odds of major diagnostic error, although it was associated with reduced odds of 
overreporting. Notably, self-identifying as a Barrett’s pathology expert, holding a dedicated 
fellowship, or reporting greater enjoyment or confidence in Barrett’s reporting were not 
associated with decreased odds of major over or underinterpretation (Supplementary Table 
8A). Finally, reporting ≥20 cases per week was associated with reduced odds of over or under-
interpretation of Barrett’s dysplasia (OR 0.69, 95%CI 0.53-0.89), although this association was 
attenuated when investigating major diagnostic errors (Supplementary Table 8B).  
Multivariate analyses before and after revealing matched p53 labelled slides 
Multivariable models were then applied, including all factors associated with collective over 
and underinterpretation on H&E digital slide review in univariate analysis, as shown in Figure 
4. At least 5 years of experience commensurate with age was the strongest protective factor 
against major diagnostic error on H&E slide review (OR 0.48, 95%CI 0.31-0.74). In contrast, 
working in a district general hospital was associated with increased odds of major diagnostic 
error (OR 1.76, 95%CI 1.15-2.69). Importantly, this effect was neutralised if pathologists in 
these settings viewed cases with additional p53 labelled slides (OR 1.44, 95%CI 0.92-2.28). 
As expected, routine use of p53 labelled slides was associated with reduced odds of major 
diagnostic error. Viewing 5-19 BO cases with p53 stained slides per week was associated with 
increased odds of major diagnostic errors, which was neutralised when viewing ≥20 cases per 
week. Most other results showed similar trends to those seen in univariate analysis, but these 
were no longer statistically significant (Figure 4).   
 
Population estimates 
To determine the impact of our results in a real-world clinical setting, we extrapolated the 
results from this case set (in which dysplastic biopsies were purposely over-represented) to 
the Barrett’s dysplasia prevalence reported from the population-based Northern Ireland 
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Barrett’s oesophagus register. As shown in Figure 5, 18.6% of all Barrett’s cases would be 
classified as having a major over- or under-interpretation, based on the findings of this study 
as applied to the real word clinical setting of H&E slide plus adjunct p53 labelled slide viewing. 
The majority of these would be attributed to potential overinterpretation of NDBO (426 out of 
461 cases, or 92.3%, Figure 5).  
 
DISCUSSION 
We have carried out the largest investigation of diagnostic concordance of BO biopsy reporting 
amongst gastrointestinal pathologists to date. Previous studies had been limited to a small 
number of expert pathologists, which meant findings were not necessarily generalizable to 
real-world settings. This work has revealed several novel findings.  
First, overall concordance for H&E digital slide review of NDBO and LGD/HGD as a 
combined outcome was excellent (exceeding 77%), although concordance for IND and LGD 
as a stand-alone diagnosis was lower (23-42%). These test characteristics replicate known 
glass slide test characteristics (Supplementary Table 1), suggesting that distant BO biopsy 
slide review is reproducible and safe.  
Second, our multivariate analyses revealed several pathologist characteristics and 
working practices independently associated with the risk of misinterpretations. Reassuringly, 
pathologist experience commensurate with age was most protective against major over- or 
underinterpretation, confirming the validity of our experimental strategy. Our multivariate 
regression analyses also confirm that working within a teaching hospital environment protects 
against major diagnostic error. This provides supportive evidence for guideline statements that 
BO complicated by dysplasia is best managed within an expert center. 21-23 26 Importantly, self-
identifying as an expert was not associated with decreased odds of major over or 
underinterpretation.  
Lastly, our study design sheds light on the context-dependent impact of p53 labelled 
slides. We find that the overall prevalence of major misinterpretations (NDBO classified as 
LGD/HGD, or vice versa) across this biopsy series enriched for IND/LGD/HGD cases was 
8.8%, which was reduced, marginally, by the addition of p53 labelled slides (8.3%). Although 
this would suggest a limited impact of the adjunct use of p53 labelled slides, our multivariate 
analysis allows us to unpack this figure and reveals that major discordance was reduced by 
viewing matched p53 labelled slides specifically for those pathologists working away from 
teaching hospital settings. This demonstrates that the beneficial impact of adjunct p53 labelled 
slides is dependent on context and is greatest outside expert centre settings where, indeed, 
most primary dysplasia diagnoses in surveillance are made. Extrapolating our concordance 
data to real-world dysplasia prevalence shows that the majority of major misdiagnoses in real 
world practice overinterpret NDBO (426 out of 461 cases, or 92.3%, Figure 5). In these cases, 
routine addition of adjunct p53 labelled slides may have substantial impact towards limiting 
overdiagnosis, although our study was not designed to examine the latter point. Routine use 
of p53 labelled slides is supported by several national guidelines, 21 23 26 and our study confirms 
that this is appropriate.  
 Taken together, our study for the first time provides an evidence-based quantitative 
model of BO histopathology diagnosis at expert consensus level. Our data reassuringly 
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suggest that BO reporting on a par with expert consensus is not limited to a small league of 
experienced histopathologists but can be predicted from a small number of intuitive 
demographic predictors (experience, professional setting, use of p53 labelled slides). This 
suggests practical interventions to reduce diagnostic variability are feasible, through improved 
training and support.  To implement routine external review of dysplastic BO biopsies, as 
mandated by several major society guidelines, requires regional or national teams of dedicated 
gastrointestinal pathologists with Barrett’s expertise. Combined with our observation that 
concordance rates for digital slide viewing were not inferior to conventional glass slide 
pathology review, 18 19 together these data suggest that distant digital review of challenging BO 
biopsy cases is safe to formally implement within current care delivery systems, provided 
quality benchmarks are met. In the Netherlands, such a set-up has been successfully 
implemented over the past five years, to accommodate nationwide digital expert review of all 
dysplastic BO biopsies. 44 45   
Our study has considerable strengths compared to previous interobserver variation 
studies of BO reporting. We have evaluated diagnostic concordance for dysplastic BO 
amongst the largest group of gastrointestinal pathologists worldwide. The heterogeneous mix 
of pathologists involved in this study also enabled novel investigations into pathologist-
dependent predictors associated with diagnostic discordance. The online reporting strategy 
mimicked routine workflow and facilitated data collection and curation in a flexible manner. The 
case set was purposely enriched for dysplastic cases in order to attain sufficient statistical 
power in our downstream regression analyses. Diagnostic concordance within a large group 
of pathologists with different levels of gastrointestinal pathology expertise was excellent for 
LGD and HGD combined. 
This study also has limitations that are important to note. One caveat to our study 
design is the original dataset which is skewed towards the inclusion of dysplastic biopsies. Our 
case-mix therefore does not represent a cross-section of diagnostic biopsy cases encountered 
in daily practice, which would be heavily weighted towards the NDBO end of the spectrum. 
Because a complete revision study whereby all consecutive surveillance biopsies are 
prospectively reviewed by a consensus panel of experienced pathologists is not practically 
feasible, we set out to extrapolate the population impact of histopathologist diagnostic variation 
from our dataset. To this end, we exploited the dysplasia population prevalence from the 
Northern Ireland Barrett’s register (see Methods) and modelled the impact of diagnostic 
variation using our concordance data (Figure 5). We found that, across all diagnostic 
categories, 81.4% of all diagnoses would be confirmed by consensus of four experienced 
Barrett’s pathologists. Given the fact that the overbearing majority of Barrett’s surveillance 
biopsies were reported to contain non-dysplastic Barrett’s mucosa, proportionally the largest 
share of diagnostic discordance is seen in this category (92.3%). Vice versa a small number 
of biopsies in routine practice (estimated at 1.3% of total) will initially be reported as non-
dysplastic Barrett’s mucosa, whereas consensus panel review would reveal high-grade 
dysplasia. These data suggest that the population impact of diagnostic variation is real and is 
most prominent for non-dysplastic Barrett’s biopsies that are overinterpreted, which may lead 
to overtreatment. A small number of patients would be undertreated despite the presence of 
abnormalities that mandate invasive management.  
A second limitation is that while our heterogeneous global group of pathologists allowed 
us to interrogate associations of a host of operator-dependent characteristics with diagnostic 
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consensus (case volume, practice setting, diagnostic experience, etc.), this study feature may 
limit the generalizability of our findings within the national setting. Replication of our findings in 
samples of pathologists within particular geographic regions adhering to one diagnostic 
guideline will be required to determine whether the quantitative predictive features described 
here are similarly applicable in that setting. Given that the majority of pathologists participating 
in this study were based either in Europe or North America, greater representation from low to 
middle income settings would be particularly welcome. This could further enhance the value 
of this recursive exercise for teaching and registration purposes.  
In conclusion, using this rich dataset of case assessments by a large, heterogeneous 
sample of gastrointestinal pathologists, we have evaluated diagnostic concordance for BO 
diagnosis using digital case review. Our results reveal quantitative predictors of diagnostic 
performance that will aid formulation of quality assurance criteria for guideline development 
and standard implementation of digital pathology in BO biopsy review.  
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FIGURE LEGENDS 
 
Figure 1:  Study design and study participants | A) Fifty-five representative BO biopsies 
with H&E slide and consecutive p53 labelled slides were collected and scanned for 
digital diagnostic review. Each pathologist on the study first completed a detailed 
demographic questionnaire (Supplementary Table 3). Pathologists then assessed 
55 biopsy cases whereby diagnostic entries on H&E slide alone and after revealing 
matched p53 labelled slides were recorded separately allowing detailed insight into 
the added benefit of p53 labelled slides on diagnostic agreement. Reference 
diagnoses were established after consensus panel meeting. Within-group 
interobserver agreement was established for reference panel (n=4) and participating 
pathologists (N=51) and multivariate regression analyses were carried out to 
interrogate demographic predictors of diagnostic concordance, as detailed in the 
text. B) Map showing geographical dispersion of pathologists participating in the 
BOLERO study. 
 
Figure 2:  Diagnostic variation across the study cohort | A) Waterfall plot showing the 
ranked distribution of case assessments (n=3,025) based on H&E slides alone for 
the entire cohort of pathologists. X-axis shows diagnostic concordance in 
percentages and y-axis shows ranked cases 1-55. Color coding as in B. B) Same 
visualisation for case assessments (n=3,025) after revealing matched p53 labelled 
slides. C) Four representative examples of the study set. Consensus diagnosis and 
cohort diagnoses are shown.  
 
Figure 3:  Diagnostic variation per reference diagnoses | A-F) Waterfall plots showing the 
ranked distribution of case assessments by participating pathologists per diagnostic 
category, as indicated. Left column (A-C) shows diagnostic variation per reference 
diagnosis based on H&E slide review alone and right column (D-F) shows diagnostic 
variation per reference diagnosis after revealing matched p53 labelled slides. X-axis 
shows diagnostic concordance in percentages and y-axis shows ranked cases. 
Color coding as in Figure 2B. Diagnostic variation for indefinite for dysplasia cases 
is shown in Supplementary Figure 1.  
 
Figure 4:   Characteristics associated with odds of major over- or under-interpretation of 
Barrett’s oesophagus with dysplasia in multivariable adjusted analysis | *All 
characteristics factors mutually adjusted for each other, **Additional adjustment for 
p53 labelled slides in routine pathology practice 
 
Figure 5:  Population level impact of diagnostic variation for Barrett’s oesophagus 
surveillance biopsies. | X-axis shows population prevalence of diagnostic classes 
where the width of each class is consistent with its proportional prevalence (total 
100%) and Y-axis shows diagnostic concordance with the total surface area adding 
up to all diagnoses made in one year. Diagnostic concordance is shown as either 
concordant (in white), overinterpreted (in blue), and underinterpreted (in magenta), 
where % shown reveal concordant diagnoses that would be confirmed for each 
diagnostic class upon review by an expert pathologist panel (Table 2).  
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Supplementary Figure 1: Diagnostic variation for indefinite for dysplasia diagnoses 
before (A) and after (B) revealing matched p53 labelled slide. X-axis shows 
diagnostic concordance in percentages and y-axis shows ranked cases. See text for 
details.  
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Table 1: Demographics of pathologists reporting in the BOLERO study 
Characteristics Participating  
pathologists  
n=51 (%) 
Reference 
panel 
pathologists  
n=4 (%) 
Pathologist specific characteristics   
Age, years 
  30-39 
  40-49 
  50-59 
  60+ 
 
13 (25.5) 
17 (33.3) 
14 (27.5) 
7 (13.7) 
 
1 (25.0) 
1 (25.0) 
1 (25.0) 
1 (25.0) 
Gender 
  Male 
  Female 
 
29 (56.9) 
22 (43.1) 
 
4 (100.0) 
0 (0.0) 
Experience, years 
  0-4 
  5-9 
  10-19 
  20+ 
 
8 (15.7) 
9 (17.7) 
18 (35.3) 
16 (31.4) 
 
1 (25.0) 
1 (25.0) 
0 (0.0) 
2 (50.0) 
Considered BE* expert? 
 Yes 
 No 
 Don’t know 
 
34 (66.7) 
8 (15.7) 
9 (17.7) 
 
4 (100.0) 
0 (0.0) 
0 (0.0) 
Confidence of assessment of BE biopsies 
 1 (very confident) 
 2 
 3 
 4 
 5 (not confident) 
 
10 (19.6) 
25 (49.0) 
13 (25.5) 
3 (5.9) 
0 (0.0) 
 
1 (25.0) 
3 (75.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
Fellowship undertaken in GI-pathology 28 (54.9) 2 (50.0) 
Pathology/endoscopy practice 
characteristics  
  
Work Setting (can be multiple settings) 
  Academic teaching hospital 
  District general hospital 
  Private hospital 
 
42 (82.4) 
16 (31.4) 
11 (21.6) 
 
3 (75.0) 
1 (25.0) 
1 (25.0) 
Mean number of BE cases assessed per 
week 
  0-4 
  5-9 
 10-19 
 20+ 
 Don’t know 
 
11 (21.6) 
16 (31.4) 
14 (27.5) 
8 (15.7) 
2 (3.9) 
 
0 (0.0) 
3 (75.0) 
1 (25.0) 
0 (0.0) 
0 (0.0) 
Lab size, number of reporting pathologists 
  <10 
  10+ 
 
14 (27.4) 
37 (72.6) 
 
0 (0.0) 
4 (100.0) 
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Table 1 continued: Demographics of pathologists reporting in the BOLERO study 
Characteristics Participating  
pathologists  
n=51 (%) 
Reference 
panel 
pathologists  
n=4 (%) 
Pathology/endoscopy practice 
characteristics  
  
Guidelines adhered to: 
  North American 
  British 
  Japanese 
  Australian 
  Other 
 
23 (45.1) 
10 (19.6) 
3 (5.9) 
1 (2.0) 
14 (27.4) 
 
2 (50.0) 
2 (50.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
p53 IHC staining routinely used? 
 Always 
 Most times 
 Sometimes 
 Never 
 
1 (2.0) 
11 (21.6) 
32 (62.8) 
7 (13.7) 
 
1 (25.0) 
1 (25.0) 
2 (50.0) 
0 (0.0) 
Digital pathology characteristics   
Use of whole slide imaging 
 Yes 
 No 
 
22 (43.1) 
29 (56.9) 
 
4 (100.0) 
0 
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Table 2: Cross table comparing the 51 participating pathologists’ diagnoses to the consensus 
derived reference diagnoses for 55 esophageal biopsy cases (a) on H&E stained slides and (b) 
on H&E and p53 labelled slides for 5,610 total case interpretations* 
 Consensu
s 
reference 
panel** 
Participating pathologists’ 
individual diagnoses 
(preconsensus) 
% Concordance 
(95% CI) 
Under-
interpretat
ion 
Over-
interpretati
on 
Concorda
nce 
a. Before addition of p53 labelled slides 
Diagnosis  ND IND LGD HGD    
NDBO 816 643 93 71 9 / 21.2 
(18.4-24.0) 
78.8 
(0.70-81.6) 
IND 306 59 70 110 67 19.2 
(14.8-23.6) 
57.8 
(52.3-63.3) 
22.9 
(18.2-27.6) 
LGD 918 151 165 382 220 34.4 
(31.3-37.5) 
24.0 
(21.2-26.8) 
41.6 
(38.4-44.8) 
HGD 765 17 45 159 544 28.9 
(25.7-32.1) 
/ 71.1 
(25.6-32.2) 
  LGD or HGD   1683 168 210 1305 22.5 
(20.4-24.5) 
/ 77.5 
(75.5-79.5) 
Total 2805        
 Consensu
s 
reference 
panel*** 
Participating pathologists’ 
individual diagnoses 
(preconsensus) 
% Concordance 
(95% CI) 
Under-
interpretat
ion 
Over-
interpretati
on 
Concorda
nce 
b. After addition of p53 labelled slides 
Diagnosis  ND IND LGD HGD    
NDBO 816 684 74 53 5 / 16.2 
(13.7-18.7) 
83.8 
(81.3-86.3) 
IND 102 36 24 27 15 35.3 
(26.0-44.6) 
41.2 
(31.6-50.8) 
23.5 
(15.3-31.7) 
LGD 1122 153 178 516 275 29.5 
(26.8-32.2) 
24.5 
(22.0-27.0) 
46.0 
(43.7-49.5) 
HGD 765 21 38 165 541 29.3 
(26.1-32.5) 
/ 70.7 
(67.8-73.9) 
  LGD or HGD   1887 174 216 1497 20.7 
(18.9-22.5) 
/ 79.3 
(77.5-81.1) 
Total 2805        
 
Table 2 Legend: *Overall concordance for 1639/2805 diagnoses (58.4%, 95%CI 56.6-60.2%); 
increasing to 2018/2805 (71.9%, 95%CI 70.2-73.6%) when LGD and HGD were combined, **Note 
consensus reference panel results are scaled x51 to allow for comparison versus the 51 participating 
pathologists. Results represent 5,610 diagnoses in 55 oesophageal biopsy cases. ***Overall 
concordance for 1765/2805 diagnoses (62.9%, 95% CI61.1-64.7%); increasing to 2205/2805 (78.6%, 
95%CI 77.1-80.1%) when LGD and HGD were combined. 
